The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting
Authors:
Open Access
- 15 October 2010
- journal article
- review article
- Published by Wiley in The Journal of Pathology
- Vol. 223 (2) , 296-307
Abstract
The directions of differentiation and the molecular features of ductal pancreatic cancer have by now been explored in reasonable detail. Already, diagnoses and therapeutic strategies benefit from observations distinguishing the major variant types of pancreatic cancer and the differing stages of disease at presentation. Additionally, individual patients differ within each variant type. In certain high‐risk groups, this permits focused screening efforts. The tumorigenic influences that characterize individual patients are increasingly considered appropriate in defining clinical treatment plans. As a result, multiple variables affect success when individualizing screening or therapy. These competing variables often limit the potential for success: some variables dominate and should receive greater consideration than others. Simplistic expectations, often falsely optimistic, for individualized care may fail to ‘pan out’ in the real world. The development of individualized care will be efficient only when the full complexity of the disease is embraced. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 84 references indexed in Scilit:
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Cellular Vaccine ApproachesThe Cancer Journal, 2010
- PLX4032, a selective BRAF V600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF WT melanoma cellsPigment Cell & Melanoma Research, 2010
- Sensitive digital quantification of DNA methylation in clinical samplesNature Biotechnology, 2009
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodiesJournal of Experimental Medicine, 2009
- DNA Methylation Alterations In Endoscopic Retrograde Cholangiopancreatography Brush Samples of Patients With Suspected Pancreaticobiliary DiseaseClinical Gastroenterology and Hepatology, 2008
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic AnalysesScience, 2008
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008
- A Familial Syndrome of Pancreatic Cancer and Melanoma with a Mutation in theCDKN2Tumor-Suppressor GeneNew England Journal of Medicine, 1995
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993